Skip directly to content

Improving Patient Care in Uncontrolled Acromegaly (IPCUA)

Pfizer is now inviting applications from Healthcare Organisations for Medical and Educational Goods and Services (MEGS) to support “Improving Patient Care in Uncontrolled Acromegaly”

 

When assessing whether a patient’s acromegaly is controlled or not, IGF-1 is an important measure to consider. A serum IGF-I level is a good measure to assess integrated GH secre¬tion and is excellent for diagnosis and monitoring. A random IGF-I value (a marker of integrated GH secretion) should be measured for diagnosis and for monitoring after a therapeutic intervention.1

 

We are particularly interested in receiving proposals that:

  • Review all acromegaly patients in order to identify those who are uncontrolled on existing treatments through medical note review.
  • Implement national guidance for acromegaly patients
  • Improve endocrine/pituitary services and pathways with the aim of improving the management of uncontrolled acromegaly patients
  • Provide an educational legacy to support improved management of acromegaly

 

Proposals for projects covering the following areas are out of scope of this call:

  • Projects bearing the name of specific medicines (medicines should only be referred to by class)
  • Projects designed to increase the uptake of a single therapeutic agent or intervention (projects should be aimed at improving adherence to specific guidelines or patient pathways)
  • Applications for funding of services which should be provided as standard within the NHS
  • Interventional or observational clinical studies
  • In vitro or in vivo (animal) studies
  • Non-interventional studies, such as epidemiological studies
  • Outcomes research studies where the primary focus is to understand the results of particular healthcare practices and interventions as well as to monitor and improve the quality of care
  • Other types of independent research on disease states, including novel diagnostic screening tools and surveys

 

Please see the Call for IPCUA Grant Application for full details of the scope of this call.

Grants will be awarded on a first come first served basis subject to the criteria set out in the Call for IPCUA Grant Applications

If you would like to submit an application please download the Grant Application Form

Once you have completed the application form please select Apply for IPCUA Grant - This will launch the online Pfizer Grants Management System.

To submit your application, complete the online registration form and upload the completed IPCUA Grant Application Form.

If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page

For general enquires or to request a meeting with a Pfizer colleagues to discuss the Improving Patient Care in Uncontrolled Acromegaly Call for Grant Applications please contact PfizerUKMEGS@Pfizer.com

To contact Pfizer for any other purpose, including adverse event reports, medical information requests, or data protection enquiries please call 01304 616161

 

References

  1. American Association of Clinical Endocrinologist: 2011 Acromegaly Guideline Update
PP-PFE-GBR-0641 / Sept 2017